The performance of companies tied to Viagra's legacy presents a challenging investment scenario . While the initial boom generated substantial gains, generic competition have significantly eroded sales . Investing in connected pharmaceutical companies now requires a discerning assessment of intellectual property rights , evolving patient changes, a